SCHEMBL4868708

SCHEMBL4868708

O=C(Nc1ccc(O)nc1)N1CCCCc2ccccc21

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.59
POLB P06746 3/20 0.57
HTR2C P28335 1/20 0.57
TP53 P04637 3/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
HTT P42858 1/20 0.56
ALDH1A1 P00352 1/20 0.56
MAPK1 P28482 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
NPC1 O15118 2/20 0.55
NFKB1 P19838 2/20 0.55
RAB9A P51151 2/20 0.55
NFKB2 Q00653 2/20 0.55
RELA Q04206 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
PKM P14618 1/20 0.55
LMNA P02545 3/20 0.54
THRB P10828 2/20 0.54
ATM Q13315 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4871071 0.87 MAPT (0.58) MAPTPOLBHTR2CTP53MEN1
SCHEMBL4863076 0.84 MAPT (0.69) MAPTPOLBTP53MEN1KMT2A
SCHEMBL4871151 0.83 MAPT (0.67) MAPTPOLBTP53MEN1KMT2A
SCHEMBL4870684 0.83 MAPT (0.67) MAPTPOLBTP53MEN1KMT2A
SCHEMBL4867471 0.82 TP53 (0.81) MAPTPOLBTP53MEN1KMT2A
SCHEMBL4869023 0.81 TP53 (0.78) MAPTPOLBTP53MEN1KMT2A
SCHEMBL4871110 0.81 TP53 (0.59) MAPTPOLBHTR2CTP53LMNA
SCHEMBL4895053 0.81 TP53 (0.64) MAPTPOLBHTR2CTP53MEN1
SCHEMBL4870658 0.80 MAPT (0.67) MAPTPOLBTP53MEN1KMT2A
SCHEMBL4869602 0.80 MAPT (0.71) MAPTPOLBTP53MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 MAPT 3398/4885POLB 2390/4885HTR2C 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.